Biologics: Targets and Therapy : Impact Factor & More
eISSN: 1177-5491pISSN: 1177-5475
Open AccessShare this on:
Key Metrics
CiteScore 
5.7
SJR
Q2Oncology
SNIP
1.05
Recommended pre-submission checks
Powered by 
Run standard language and technical checks to improve your manuscript – before you submit
Technical Compliance
Ensure manuscript complies with standard submission guidelines.
Language Quality
Improve clarity, grammar, and academic writing style.
A comprehensive report covering all these checks awaits you.
Biologics: Targets and Therapy Journal Specifications
| Overview | |
| Publisher | DOVE MEDICAL PRESS LTD |
| Language | English |
| Frequency | Continuous publication |
| Article Processing Charges | USD 2390 |
| Publication Time | 16 |
| Editorial Review Process | Anonymous peer review |
| General Details | |
| Language | English |
| Frequency | Continuous publication |
| Publication Start Year | 2007 |
| Publisher URL | Visit website |
| Website URL | Visit website |
| Publication Details | |
| Editorial Review Detail | |
| Information for authors | |
| Author instructions | Visit website |
| Copyright Details | Visit website |
| Deposit Policy | Sherpa/Romeo |
| License type | CC BY, CC BY-NC |
| OA statement | Visit website |
View less
Planning to publish in Biologics: Targets and Therapy ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in Biologics: Targets and Therapy
Teclistamab for Relapsed or Refractory Multiple Myeloma: A Review of Efficacy, Safety, Resistance Mechanisms and Future Directions
- 13 Jan 2026
- Biologics : Targets & Therapy
Research on the Role of Autophagy in Vascular Endothelial Cells in the Healing of Chronic Refractory Wounds
- 1 Jan 2026
- Biologics: Targets and Therapy
Successful and Risk-Minimizing Treatment of Ulcerative Colitis by Positive Switch from JAK Inhibitors to Ustekinumab
- 1 Jan 2026
- Biologics: Targets and Therapy
Mesenchymal Stem Cell Therapy in Osteoarthritis and Rheumatoid Arthritis: A Systematic Review of Exosomal microRNAs
- 30 Dec 2025
- Biologics : Targets & Therapy
Mechanism and Applications of CRISPR/Cas-9-Mediated Genome Editing [Corrigendum]
- 27 Dec 2025
- Biologics : Targets & Therapy
Efficacy, Safety, and Cost-Effectiveness of the Infliximab Biosimilar GP-1111 in Patients with Inflammatory Bowel Disease Who Underwent a Nonmedical Switch: A Prospective Cohort Study
- 18 Dec 2025
- Biologics : Targets & Therapy
Teclistamab for Relapsed or Refractory Multiple Myeloma: A Review of Efficacy, Safety, Resistance Mechanisms and Future Directions
- 13 Jan 2026
- Biologics : Targets & Therapy
Research on the Role of Autophagy in Vascular Endothelial Cells in the Healing of Chronic Refractory Wounds
- 1 Jan 2026
- Biologics: Targets and Therapy
Successful and Risk-Minimizing Treatment of Ulcerative Colitis by Positive Switch from JAK Inhibitors to Ustekinumab
- 1 Jan 2026
- Biologics: Targets and Therapy
Mesenchymal Stem Cell Therapy in Osteoarthritis and Rheumatoid Arthritis: A Systematic Review of Exosomal microRNAs
- 30 Dec 2025
- Biologics : Targets & Therapy
Mechanism and Applications of CRISPR/Cas-9-Mediated Genome Editing [Corrigendum]
- 27 Dec 2025
- Biologics : Targets & Therapy
Efficacy, Safety, and Cost-Effectiveness of the Infliximab Biosimilar GP-1111 in Patients with Inflammatory Bowel Disease Who Underwent a Nonmedical Switch: A Prospective Cohort Study
- 18 Dec 2025
- Biologics : Targets & Therapy
FAQs on Biologics: Targets and Therapy
How long has Biologics: Targets and Therapy been actively publishing? 
What is the publishing frequency of Biologics: Targets and Therapy?
How many articles did Biologics: Targets and Therapy publish last year?
What is the eISSN & pISSN for Biologics: Targets and Therapy?
What is Citescore for Biologics: Targets and Therapy?
What is SNIP score for Biologics: Targets and Therapy?
What is the SJR for Biologics: Targets and Therapy?
Who is the publisher of Biologics: Targets and Therapy?
